FDA Approves Lusedra Injection for Monitored Anesthesia Care Sedation

Eisai Corp. has announced that the FDA has approved its Lusedra (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care sedation.

Advertisement

The injection is for use in adult patients undergoing diagnostic or therapeutic procedures.

Read Eisai’s press release about the Lusedra approval.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.